Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse and / or Refractory Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06375044
What this trial is testing

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd. 130
Early research (Phase 1)Ended earlyNCT05289492
What this trial is testing

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
iTeos Therapeutics 16
Very early researchLooking for participantsNCT04657861
What this trial is testing

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Zhejiang University 36
Early research (Phase 1)Study completedNCT04322292
What this trial is testing

BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 9
Early research (Phase 1)Ended earlyNCT03582033
What this trial is testing

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Seagen Inc. 83
Early research (Phase 1)Study completedNCT02519452
What this trial is testing

Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 120
Very early researchNot Yet RecruitingNCT06986434
What this trial is testing

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

Who this might be right for
Relapsed or Refractory Plasma Cell NeoplasmsLymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences 20
Testing effectiveness (Phase 2)Study completedNCT02963493
What this trial is testing

Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Oncopeptides AB 157
Testing effectiveness (Phase 2)Ended earlyNCT00017069
What this trial is testing

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
CTI BioPharma
Early research (Phase 1)Study completedNCT02561962
What this trial is testing

Study in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Amgen 42
Early research (Phase 1)Study completedNCT01122875
What this trial is testing

The Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genentech, Inc. 14
Large-scale testing (Phase 3)Not Yet RecruitingNCT06742138
What this trial is testing

To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Qilu Pharmaceutical Co., Ltd. 284
Not applicableApproved For MarketingNCT05463939
What this trial is testing

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Large-scale testing (Phase 3)Study completedNCT03952091
What this trial is testing

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseRefractory Multiple Myeloma
TJ Biopharma Co., Ltd. 289
Testing effectiveness (Phase 2)Study completedNCT00006013
What this trial is testing

SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Fox Chase Cancer Center 21
Early research (Phase 1)Study completedNCT02332850
What this trial is testing

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Thomas Martin, MD 83
Early research (Phase 1)Study completedNCT00932698
What this trial is testing

Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma
Millennium Pharmaceuticals, Inc. 60
Large-scale testing (Phase 3)Looking for participantsNCT07222761
What this trial is testing

Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 915
Early research (Phase 1)Study completedNCT00545519
What this trial is testing

A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

Who this might be right for
Relapsed Or Refractory Multiple Myeloma
Washington University School of Medicine 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT03989414
What this trial is testing

Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Celgene 424
Next Page